Catalyst Wire Dossier Catalyst Wire Dossier

SB5

adalimumab biosimilar · Samsung Bioepis Co., Ltd.
Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for SB5, covering 2017-01-19 to 2023-05-25. Get the full timeline:

Most recent: Clinical Trial Update: Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis [Phase 4]

See pricing